These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 31192473)
1. Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy. Loonstra FC; Verberk IMW; Wijburg MT; Wattjes MP; Teunissen CE; van Oosten BW; Uitdehaag BMJ; Killestein J; van Kempen ZLE Ann Neurol; 2019 Aug; 86(2):322-324. PubMed ID: 31192473 [No Abstract] [Full Text] [Related]
2. Reply to "Serum Neurofilaments as Candidate Biomarkers of Natalizumab Progressive Multifocal Leukoencephalopathy". Dalla Costa G; Martinelli V; Furlan R; Comi G Ann Neurol; 2019 Aug; 86(2):324. PubMed ID: 31187511 [No Abstract] [Full Text] [Related]
3. Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk. Marignier R; Durand-Dubief F; du Pasquier R; Vukusic S Ann Neurol; 2016 Nov; 80(5):791. PubMed ID: 27554031 [No Abstract] [Full Text] [Related]
4. Metalloproteinase 9 as a biomarker of progressive multifocal leukoencephalopathy development in multiple sclerosis patients receiving natalizumab. Zahednasab H; Harirchian MH; Karampoor S; Keyvani H Ann Neurol; 2017 Oct; 82(4):647. PubMed ID: 28869674 [No Abstract] [Full Text] [Related]
5. Commentary on "Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis". Arrambide G Mult Scler; 2017 Mar; 23(3):486-487. PubMed ID: 28260414 [No Abstract] [Full Text] [Related]
14. The 'across the pons' sign: A possible novel radiographic finding in natalizumab-associated progressive multifocal leukoencephalopathy. Budhram A; Pelikan JB; Kremenchutzky M; Sharma M J Neurol Sci; 2017 Apr; 375():304-306. PubMed ID: 28320156 [No Abstract] [Full Text] [Related]
15. Extended-interval dosing of natalizumab in NOVA - Authors' reply. Foley JF; Campbell N; Kong G Lancet Neurol; 2023 Mar; 22(3):200-201. PubMed ID: 36804085 [No Abstract] [Full Text] [Related]
16. Progressive multifocal leukoencephalopathy in the era of new disease-modifying treatments for multiple sclerosis. Filippi-Arriaga F; Riera-Arnau J; Rodríguez-Acevedo B; Bosch Ferrer M Med Clin (Barc); 2021 May; 156(10):509-514. PubMed ID: 33431183 [No Abstract] [Full Text] [Related]
17. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy]. Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945 [TBL] [Abstract][Full Text] [Related]
18. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis. Rath L; Vijiaratnam N; Skibina O Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809 [TBL] [Abstract][Full Text] [Related]
19. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations. Warnke C; Hartung HP Mult Scler; 2017 Jun; 23(7):920-922. PubMed ID: 28481191 [No Abstract] [Full Text] [Related]
20. Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks. Maloney E; Molloy A; Al Hussona M; O'Donnell L; Killeen R; McGuigan C J Neurol; 2017 Feb; 264(2):401-403. PubMed ID: 28039520 [No Abstract] [Full Text] [Related] [Next] [New Search]